| Victims' advocate sues asbestos attorneys for gypping her
Victims' advocate Judy Buckles once said, "Madison County is the best when it comes to representing asbestos victims and their families." On Wednesday she filed a legal malpractice suit against two of the county's busiest asbestos litigators.
Buckles, whose husband died from mesothelioma in 1997, alleges her former lawyers entered into secret agreements with asbestos defendants to settle claims for absurd predetermined amounts of money when the "reasonable value" of mesothelioma claims were worth millions of dollars.
Asbestos lawyers Hopkins Goldenberg -- now known as Goldenberg, Heller, Antognoli, Rowland, Short & Gori -- John Simmons, William Miller and SimmonsCooper LLC were named as defendants in the lawsuit filed July 12 in Madison County Circuit Court.
Buckles is represented by Roy Dripps of the Lakin Law Firm of Wood River.
workers strain to keep healthy
PUSHING a drawing pin into a notice board doesnt seem risky, but for 140 education workers it has turned out to be fatal. The Times Educational Supplement (July 7) reports on research by Dr Robin Howie, an occupational hygiene consultant, who found that removing a single pin from an asbestos board can release about 6,000 fibres in theory a single fibre can cause a tumour. Asbestos is thought to be present in most British schools and Health and Safety Executive figures show that 140 education workers, many teachers, died of mesothelioma between 1991 and 2000. Another profession that faces daily danger is the Metropolitan Police force but, according to Police Review (July 7), their hearts are in the right state: 86 per cent of the Mets workforce have cholesterol levels within normal range, .
Cambridge Antibody Technology Announces Acquisition of Oncology ...
CAMBRIDGE, England, July 27 /PRNewswire/ -- Cambridge Antibody Technology (CAT) announces the acquisition of product candidate SS1P (renamed CAT-5001) from Enzon Pharmaceuticals, Inc., based in Bridgewater, New Jersey in May 2006. The safety profile of CAT-5001 has been characterised in two Phase I clinical trials in patients with mesothelioma, ovarian and pancreatic cancer. CAT intends to conduct further pre-clinical studies and to initiate a clinical study in early 2007 exploring dosing of CAT-5001 in combination with cytotoxic chemotherapy. CAT-5001 was discovered and initially developed by the National Cancer Institute (NCI), which is part of the US National Institutes of Health (NIH). The programme was licensed to Enzon and that licence has now been assigned to CAT. Under the original licence agreement with the NIH, CAT will have rights to a portfolio of intellectual property associated with the programmes and will pay future royalties to NIH.
CuraGen Reports Second Quarter 2006 Financial Results
BRANFORD, Conn., July 27 /PRNewswire-FirstCall/ -- CuraGen Corporation CRGN today reported its consolidated financial results for the second quarter 2006. For the quarter ended June 30, 2006, CuraGen's consolidated net loss was $14.3 million, or $0.26 per share, compared to a net loss of $15.7 million, or $0.31 per share, for the same period in 2005. As of June 30, 2006, CuraGen had available cash and investments of $193.6 million, as compared to $211.3 million at March 31, 2006, and had outstanding 6% convertible debt of $66.2 million, due February 2007, and 4% convertible debt of $110 million, due February 2011. CuraGen also announced today it has formally engaged Goldman Sachs to examine strategic options for CuraGen's investment in 454 Life Sciences. In the second quarter of 2006, 454 Life Sciences, CuraGen's majority-owned subsidiary, recognized a total of $9.8 million in revenue, a 188% increase compared to the same period in 2005.
|
